Capivasertib Cost-Effectiveness in Advanced Bre...

By Rene Pretorius

April 18, 2025

Capivasertib, a novel AKT inhibitor, has gained approval as a second-line therapy for advanced breast cancer, but its high cost has sparked concerns about ...
Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critic...
Sugary Drinks Cancer Risk: Women Face Higher Oral Cavity Cancer Threat
Cost-Effective HIV PrEP: CAB-LA Transforms Prevention
Neoadjuvant Immunotherapy Efficacy: Enhancing Treatment Strategies for Head a...
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Cost-Effective Interventions for HIV, Malaria, Syphilis, and TB in 128 Countries
Challenges in Accelerating Innovative Paediatric Medicine
Balancing Pandemic Preparedness Priorities and Military Spending
Exploring the MASLD CKD Socioeconomic Link
Toripalimab Evidence Journey in Cancer Care
Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, an...
Cancer Control Month 2025: Key Takeaways from President Trump’s National Call...